<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns="http://purl.org/rss/1.0/">
<channel rdf:about="http://www.nature.com/ncpendmet/current_issue/rss">
<title>Nature Clinical Practice Endocrinology &amp; Metabolism</title>
<description>Nature Clinical Practice Endocrinology &amp; Metabolism provides physicians with authoritative and timely interpretations of key developments in the field, translating the latest findings into clinical practice.</description>
<link>http://www.nature.com/ncpendmet/current_issue/</link>
<dc:publisher>Nature Publishing Group</dc:publisher>
<dc:language>en</dc:language>
<dc:rights>&#169;  Nature Publishing Group</dc:rights>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:issn>1745-8366</prism:issn>
<prism:eIssn>1745-8374</prism:eIssn>
<prism:copyright>&#169;  Nature Publishing Group</prism:copyright>
<prism:rightsAgent>permissions@nature.com</prism:rightsAgent>
<image rdf:resource="http://www.nature.com/includes/rj_globnavimages/ncpendmet_logo.gif"/>
<items>
<rdf:Seq>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet1019"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet1021"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet1018"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet1020"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0981"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0979"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0997"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet1004"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0984"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0983"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0970"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0977"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0969"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet1007"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet1001"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0975"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0971"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet1003"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet1005"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0995"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0980"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0985"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0998"/>
</rdf:Seq>
</items>
</channel>
<image rdf:about="http://www.nature.com/includes/rj_globnavimages/ncpendmet_logo.gif">
<title>Nature Clinical Practice Endocrinology &amp; Metabolism</title>
<url>http://www.nature.com/includes/rj_globnavimages/ncpendmet_logo.gif</url>
<link>http://www.nature.com/ncpendmet/</link>
</image>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet1019">
<title>Pregabalin for painful diabetic peripheral neuropathy</title>
<link>http://dx.doi.org/10.1038/ncpendmet1019</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Pregabalin for painful diabetic peripheral neuropathy</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet1019">doi:10.1038/ncpendmet1019</a>
</p>
<p>Authors: Lee C Rogers
&amp; David G Armstrong</p>
]]></content:encoded>
<dc:title>Pregabalin for painful diabetic peripheral neuropathy</dc:title>
<dc:creator>Lee C Rogers</dc:creator>
<dc:creator>David G Armstrong</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet1019</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-11-18</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-11-18</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet1021">
<title>Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus</title>
<link>http://dx.doi.org/10.1038/ncpendmet1021</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet1021">doi:10.1038/ncpendmet1021</a>
</p>
<p>Authors: Konstantinos Tziomalos, Vasilios G Athyros
&amp; Dimitri P Mikhailidis</p>
]]></content:encoded>
<dc:title>Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus</dc:title>
<dc:creator>Konstantinos Tziomalos</dc:creator>
<dc:creator>Vasilios G Athyros</dc:creator>
<dc:creator>Dimitri P Mikhailidis</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet1021</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-11-18</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-11-18</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet1018">
<title>Should serial assessment of bone turnover markers be included in fracture risk calculation in elderly women?</title>
<link>http://dx.doi.org/10.1038/ncpendmet1018</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Should serial assessment of bone turnover markers be included in fracture risk calculation in elderly women?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet1018">doi:10.1038/ncpendmet1018</a>
</p>
<p>Author: Samuel D Vasikaran</p>
]]></content:encoded>
<dc:title>Should serial assessment of bone turnover markers be included in fracture risk calculation in elderly women?</dc:title>
<dc:creator>Samuel D Vasikaran</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet1018</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-11-18</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-11-18</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet1020">
<title>Routine screening for germline RET mutations is recommended for all patients with medullary thyroid cancer</title>
<link>http://dx.doi.org/10.1038/ncpendmet1020</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Routine screening for germline RET mutations is recommended for all patients with medullary thyroid cancer</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet1020">doi:10.1038/ncpendmet1020</a>
</p>
<p>Authors: Diana L Learoyd
&amp; Bruce G Robinson</p>
]]></content:encoded>
<dc:title>Routine screening for germline RET mutations is recommended for all patients with medullary thyroid cancer</dc:title>
<dc:creator>Diana L Learoyd</dc:creator>
<dc:creator>Bruce G Robinson</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet1020</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-11-11</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-11-11</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0981">
<title>Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0981</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0981">doi:10.1038/ncpendmet0981</a>
</p>
<p>Author: Sherri-Ann M Burnett-Bowie</p>
]]></content:encoded>
<dc:title>Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture?</dc:title>
<dc:creator>Sherri-Ann M Burnett-Bowie</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0981</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-11-04</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-11-04</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0979">
<title>Does vitamin D3 dosing schedule influence treatment efficacy in nursing home residents with vitamin D deficiency?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0979</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Does vitamin D3 dosing schedule influence treatment efficacy in nursing home residents with vitamin D deficiency?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0979">doi:10.1038/ncpendmet0979</a>
</p>
<p>Author: Michael F Holick</p>
]]></content:encoded>
<dc:title>Does vitamin D3 dosing schedule influence treatment efficacy in nursing home residents with vitamin D deficiency?</dc:title>
<dc:creator>Michael F Holick</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0979</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-10-28</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-10-28</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0997">
<title>Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0997</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0997">doi:10.1038/ncpendmet0997</a>
</p>
<p>Authors: Lars Ryd&#233;n, Klas Malmberg
&amp; Linda Mellbin</p>
]]></content:encoded>
<dc:title>Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?</dc:title>
<dc:creator>Lars Ryd&#233;n</dc:creator>
<dc:creator>Klas Malmberg</dc:creator>
<dc:creator>Linda Mellbin</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0997</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-10-28</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-10-28</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet1004">
<title>Does serum TSH level have thyroid hormone independent effects on bone turnover?</title>
<link>http://dx.doi.org/10.1038/ncpendmet1004</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Does serum TSH level have thyroid hormone independent effects on bone turnover?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet1004">doi:10.1038/ncpendmet1004</a>
</p>
<p>Author: Graham R Williams</p>
]]></content:encoded>
<dc:title>Does serum TSH level have thyroid hormone independent effects on bone turnover?</dc:title>
<dc:creator>Graham R Williams</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet1004</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-10-28</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-10-28</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0984">
<title>Vertebral fracture assessment using standard bone densitometry equipment predicts incident fractures in women</title>
<link>http://dx.doi.org/10.1038/ncpendmet0984</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Vertebral fracture assessment using standard bone densitometry equipment predicts incident fractures in women</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0984">doi:10.1038/ncpendmet0984</a>
</p>
<p>Authors: Mary L Bouxsein
&amp; Pierre D Delmas</p>
]]></content:encoded>
<dc:title>Vertebral fracture assessment using standard bone densitometry equipment predicts incident fractures in women</dc:title>
<dc:creator>Mary L Bouxsein</dc:creator>
<dc:creator>Pierre D Delmas</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0984</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-10-07</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-10-07</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0983">
<title>Could renin inhibition be the next step forward in the treatment of diabetic kidney disease?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0983</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Could renin inhibition be the next step forward in the treatment of diabetic kidney disease?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0983">doi:10.1038/ncpendmet0983</a>
</p>
<p>Author: Katherine R Tuttle</p>
]]></content:encoded>
<dc:title>Could renin inhibition be the next step forward in the treatment of diabetic kidney disease?</dc:title>
<dc:creator>Katherine R Tuttle</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0983</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-10-07</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-10-07</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0970">
<title>Should the levothyroxine starting dose be tailored to disease severity in neonates with congenital hypothyroidism?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0970</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Should the levothyroxine starting dose be tailored to disease severity in neonates with congenital hypothyroidism?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0970">doi:10.1038/ncpendmet0970</a>
</p>
<p>Author: Stephen H LaFranchi</p>
]]></content:encoded>
<dc:title>Should the levothyroxine starting dose be tailored to disease severity in neonates with congenital hypothyroidism?</dc:title>
<dc:creator>Stephen H LaFranchi</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0970</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-09-30</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-09-30</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0977">
<title>Is megestrol acetate a suitable option for treatment of hot flashes in women with breast cancer?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0977</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Is megestrol acetate a suitable option for treatment of hot flashes in women with breast cancer?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0977">doi:10.1038/ncpendmet0977</a>
</p>
<p>Author: Michelle P Warren</p>
]]></content:encoded>
<dc:title>Is megestrol acetate a suitable option for treatment of hot flashes in women with breast cancer?</dc:title>
<dc:creator>Michelle P Warren</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0977</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-09-30</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-09-30</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0969">
<title>Metformin therapy for gestational diabetes mellitus: are we there yet?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0969</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Metformin therapy for gestational diabetes mellitus: are we there yet?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0969">doi:10.1038/ncpendmet0969</a>
</p>
<p>Author: Denice S Feig</p>
]]></content:encoded>
<dc:title>Metformin therapy for gestational diabetes mellitus: are we there yet?</dc:title>
<dc:creator>Denice S Feig</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0969</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-09-23</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-09-23</prism:publicationDate>
<prism:section>Practice Point</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet1007">
<title>Inhaled insulin&#8212;what went wrong</title>
<link>http://dx.doi.org/10.1038/ncpendmet1007</link>
<description>FDA approval of inhaled insulin offered the possibility of a new direction in diabetes care. Nonetheless, within a year of coming to market, the first inhaled insulin product was withdrawn by the manufacturer. Here, Mitri and Pittas examine the factors behind the failure of inhaled insulin to be adopted by patients and clinicians.</description>
<content:encoded><![CDATA[

<p>
<b>Inhaled insulin&#8212;what went wrong</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet1007">doi:10.1038/ncpendmet1007</a>
</p>
<p>Authors: Joanna Mitri
&amp; Anastassios G Pittas</p>
]]></content:encoded>
<dc:title>Inhaled insulin&#8212;what went wrong</dc:title>
<dc:creator>Joanna Mitri</dc:creator>
<dc:creator>Anastassios G Pittas</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet1007</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-11-04</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-11-04</prism:publicationDate>
<prism:section>Viewpoint</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet1001">
<title>The role of antipsychotic agents in the development of diabetes mellitus</title>
<link>http://dx.doi.org/10.1038/ncpendmet1001</link>
<description>Use of the second-generation (atypical) antipsychotic agents has led to concerns about possible adverse metabolic effects, including an increased risk of diabetes mellitus. The potential mechanisms underlying treatment-emergent diabetes mellitus, and strategies for effective management of affected individuals, are explored by the author of this Viewpoint.</description>
<content:encoded><![CDATA[

<p>
<b>The role of antipsychotic agents in the development of diabetes mellitus</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet1001">doi:10.1038/ncpendmet1001</a>
</p>
<p>Author: Samuel Dagogo-Jack</p>
]]></content:encoded>
<dc:title>The role of antipsychotic agents in the development of diabetes mellitus</dc:title>
<dc:creator>Samuel Dagogo-Jack</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet1001</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-10-28</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-10-28</prism:publicationDate>
<prism:section>Viewpoint</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0975">
<title>Endoscopic surgery for cystic lesions of the pituitary region</title>
<link>http://dx.doi.org/10.1038/ncpendmet0975</link>
<description>Cystic lesions of the pituitary region are quite common but present a challenge for diagnosis and treatment. Several types of cystic lesion are recognized, including cystic pituitary adenomas, Rathke cleft cysts, arachnoid cysts, and craniopharyngiomas. The clinical symptoms and diagnosis of these lesions, and the use of endoscopy for surgical intervention, are discussed in this Viewpoint.</description>
<content:encoded><![CDATA[

<p>
<b>Endoscopic surgery for cystic lesions of the pituitary region</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0975">doi:10.1038/ncpendmet0975</a>
</p>
<p>Author: Edward R Laws</p>
]]></content:encoded>
<dc:title>Endoscopic surgery for cystic lesions of the pituitary region</dc:title>
<dc:creator>Edward R Laws</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0975</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-10-07</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-10-07</prism:publicationDate>
<prism:section>Viewpoint</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0971">
<title>Insulin therapy versus cell-based therapy for type 1 diabetes mellitus: what lies ahead?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0971</link>
<description>Current approaches to treat type 1 diabetes mellitus can be divided into three categories: insulin therapy, cell-based therapy and modification of the autoimmune process associated with type 1 diabetes mellitus. Comparing the benefits, risk and challenges of insulin therapy and cell-based therapy, the author of this Viewpoint discusses the prospects for these two therapeutic approaches.</description>
<content:encoded><![CDATA[

<p>
<b>Insulin therapy versus cell-based therapy for type 1 diabetes mellitus: what lies ahead?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0971">doi:10.1038/ncpendmet0971</a>
</p>
<p>Author: Alvin C Powers</p>
]]></content:encoded>
<dc:title>Insulin therapy versus cell-based therapy for type 1 diabetes mellitus: what lies ahead?</dc:title>
<dc:creator>Alvin C Powers</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0971</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-09-30</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-09-30</prism:publicationDate>
<prism:section>Viewpoint</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet1003">
<title>Ghrelin as a pleotrophic modulator of gonadal function and reproduction</title>
<link>http://dx.doi.org/10.1038/ncpendmet1003</link>
<description>The gut hormone ghrelin is a putative signal of energy balance. In addition, ghrelin might act as a pleotrophic modulator of reproductive function. The experimental and clinical data that support a role for ghrelin in the hypothalamic&#8211;pituitary&#8211;gonadal axis are summarized by the author of this Review.</description>
<content:encoded><![CDATA[

<p>
<b>Ghrelin as a pleotrophic modulator of gonadal function and reproduction</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet1003">doi:10.1038/ncpendmet1003</a>
</p>
<p>Author: Manuel Tena-Sempere</p>
]]></content:encoded>
<dc:title>Ghrelin as a pleotrophic modulator of gonadal function and reproduction</dc:title>
<dc:creator>Manuel Tena-Sempere</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet1003</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-11-04</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-11-04</prism:publicationDate>
<prism:section>Review</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet1005">
<title>Treating fetal thyroid and adrenal disorders through the mother</title>
<link>http://dx.doi.org/10.1038/ncpendmet1005</link>
<description>As genetic and imaging techniques advance, more is becoming known about the nature of various fetal disorders. Some of these disorders may be treated, with varying degrees of success, through the mother. This Review presents information particularly on fetal adrenal and thyroid disorders and discusses the various management approaches and their related risks and outcomes.</description>
<content:encoded><![CDATA[

<p>
<b>Treating fetal thyroid and adrenal disorders through the mother</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet1005">doi:10.1038/ncpendmet1005</a>
</p>
<p>Authors: Guy Van Vliet, Michel Polak
&amp; E Martin Ritz&#233;n</p>
]]></content:encoded>
<dc:title>Treating fetal thyroid and adrenal disorders through the mother</dc:title>
<dc:creator>Guy Van Vliet</dc:creator>
<dc:creator>Michel Polak</dc:creator>
<dc:creator>E Martin Ritz&#233;n</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet1005</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-11-04</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-11-04</prism:publicationDate>
<prism:section>Review</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0995">
<title>Mechanisms related to the pathophysiology and management of central hypothyroidism</title>
<link>http://dx.doi.org/10.1038/ncpendmet0995</link>
<description>The prevalence of central hypothyroidism is unknown, but might be greater than reported. This disorder may arise from a variety of causes, from tumor-related hormonal disturbances, to mechanical problems related to traumatic brain injury, to being induced by drug therapy. This Review presents an overview of etiologies, diagnosis and management.</description>
<content:encoded><![CDATA[

<p>
<b>Mechanisms related to the pathophysiology and management of central hypothyroidism</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0995">doi:10.1038/ncpendmet0995</a>
</p>
<p>Authors: Masanobu Yamada
&amp; Masatomo Mori</p>
]]></content:encoded>
<dc:title>Mechanisms related to the pathophysiology and management of central hypothyroidism</dc:title>
<dc:creator>Masanobu Yamada</dc:creator>
<dc:creator>Masatomo Mori</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0995</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-10-21</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-10-21</prism:publicationDate>
<prism:section>Review</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0980">
<title>Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9</title>
<link>http://dx.doi.org/10.1038/ncpendmet0980</link>
<description>Aquaporin subtypes 7 and 9 have vital roles in the control of glycerol channels in adipocytes and hepatocytes, and thereby the balance between glycerol release and uptake by adipocytes and the liver, respectively. This Review discusses the pathophysiological importance of these channels in obesity and related disorders.</description>
<content:encoded><![CDATA[

<p>
<b>Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0980">doi:10.1038/ncpendmet0980</a>
</p>
<p>Authors: Norikazu Maeda, Tohru Funahashi
&amp; Iichiro Shimomura</p>
]]></content:encoded>
<dc:title>Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9</dc:title>
<dc:creator>Norikazu Maeda</dc:creator>
<dc:creator>Tohru Funahashi</dc:creator>
<dc:creator>Iichiro Shimomura</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0980</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-10-14</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-10-14</prism:publicationDate>
<prism:section>Review</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0985">
<title>A patient with ectopic cortisol production derived from malignant testicular masses</title>
<link>http://dx.doi.org/10.1038/ncpendmet0985</link>
<description>This article describes a patient with Cushing syndrome presumably attributable to an adrenocortical carcinoma arising from testicular adrenal rest cells. The authors discuss treatment options for adrenocorticotropic hormone-independent hypercortisolism and highlight the difficulties in determining the origin of ectopic cortisol production.</description>
<content:encoded><![CDATA[

<p>
<b>A patient with ectopic cortisol production derived from malignant testicular masses</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0985">doi:10.1038/ncpendmet0985</a>
</p>
<p>Authors: Shilpa H Jain, Peter M Sadow, Vania Nos&#233;
&amp; Robert G Dluhy</p>
]]></content:encoded>
<dc:title>A patient with ectopic cortisol production derived from malignant testicular masses</dc:title>
<dc:creator>Shilpa H Jain</dc:creator>
<dc:creator>Peter M Sadow</dc:creator>
<dc:creator>Vania Nos&#233;</dc:creator>
<dc:creator>Robert G Dluhy</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0985</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-10-21</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-10-21</prism:publicationDate>
<prism:section>Case Study</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0998">
<title>How do detemir and glargine compare when added to oral agents in insulin-na&#239;ve patients with type 2 diabetes mellitus?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0998</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>How do detemir and glargine compare when added to oral agents in insulin-na&#239;ve patients with type 2 diabetes mellitus?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism. <a href="http://dx.doi.org/10.1038/ncpendmet0998">doi:10.1038/ncpendmet0998</a>
</p>
<p>Author: Jennifer B Marks</p>
]]></content:encoded>
<dc:title>How do detemir and glargine compare when added to oral agents in insulin-na&#239;ve patients with type 2 diabetes mellitus?</dc:title>
<dc:creator>Jennifer B Marks</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0998</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism</dc:source>
<dc:date>2008-11-04</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-11-04</prism:publicationDate>
<prism:section>Corrigendum</prism:section>
<prism:startingPage/>
<prism:endingPage/>
</item>
</rdf:RDF>
